Enjoy complimentary customisation on priority with our Enterprise License!
The non-cancerous skin diseases therapeutics market size is forecast to increase by USD 25.22 billion at a CAGR of 9.88% between 2023 and 2028. The market is experiencing significant growth due to the high prevalence of skin diseases worldwide. According to the World Health Organization, approximately 25% of the global population suffers from various skin conditions. A key trend in the market is the increased focus on microbiome and skin barrier research, leading to the development of innovative therapies. Another growth factor is the rising demand for effective treatments for common skin diseases such as acne, psoriasis, and eczema. However, the market faces challenges from increasing competition, particularly from local companies offering generic drugs at low price points. This competition puts pressure on market players to differentiate themselves through product innovation and effective marketing strategies. Additionally, stringent regulatory requirements and high development costs are other challenges that market players must navigate to remain competitive.
The market encompasses a range of treatments for various conditions, excluding skin cancer. Melanoma, a type of skin cancer, is distinguished from other non-cancerous skin diseases. However, some chronic skin diseases, such as uveal melanoma (mUM), can be immunocompromised patients' concerns. Key therapeutic approaches for non-melanoma skin diseases include targeted therapy, immunotherapy, and surgery. For instance, KIMMTRAK (tebentafusp) and KEYTRUDA are immunotherapies used for treating advanced melanoma in some cases. Lymphocyte activation gene 3 assay is a diagnostic tool used to identify patients likely to respond to immune checkpoint inhibitors, such as Pembrolizumab and Nivolumab. Other therapies include chemotherapy, cellular therapy, and combination therapies.
Desmoplastic melanoma, a rare and aggressive form of melanoma, may require targeted therapies or immunotherapies. Novel immunotherapies and combination therapies are emerging as potential treatments for various non-cancerous skin diseases, offering new hope for patients. In summary, the market comprises various treatments, including targeted therapies, immunotherapies, surgery, and chemotherapy, for various non-melanoma skin diseases. Immunotherapies, such as immune checkpoint inhibitors, are gaining popularity due to their potential to improve patient outcomes.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD Billion" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.
The psoriasis segment is estimated to witness significant growth during the forecast period. Non-cancerous skin diseases, such as psoriasis, pose a significant health challenge to millions of people worldwide. According to the American Academy of Dermatology (AAD), psoriasis is a chronic, noncommunicable skin condition that affects over 125 million individuals globally. This disease is characterized by an accelerated lifestyle of skin cells, resulting in the formation of scales and red patches on the skin surface. The root cause of psoriasis is an abnormality in the immune system, which may also lead to mental health issues and comorbidities like cardiovascular diseases and diabetes. Plaque psoriasis is the most common type, accounting for 80%-90% of cases.
Skin cancer, including melanoma, is another prevalent non-communicable skin disease. Melanoma is a malignant tumor that originates in melanocytes, the pigment-producing cells in the skin. Immunocompromised individuals and those in intensive care settings are at a higher risk of developing melanoma and other skin cancers due to their weakened immune systems. In the diagnostics and therapeutics sector, there is ongoing research and development for skin cancer, including melanoma. Targeted therapies, such as immunotherapy and chemotherapy, are being explored for the treatment of metastatic melanoma and desmoplastic melanoma. Amtagvi (lifileucel) and extracellular vesicles are among the novel therapeutic approaches. Genetic mutations play a crucial role in the development of skin cancer, and understanding these mutations is essential for precision medicine.
Ozone layer depletion and UV radiation exposure are environmental factors that contribute to the development of skin diseases, including skin cancer. Branded and generic drugs, as well as surgical interventions like broad local excision and skin grafting, are among the available treatment options for various non-cancerous and cancerous skin diseases. Immune checkpoint inhibitors, such as Pembrolizumab and Nivolumab, are among the targeted immunotherapies that have shown promising results in clinical trials. Novel immunotherapies and combination therapies are also under investigation to improve treatment efficacy and address drug resistance. Early detection and addressing genetic predispositions are essential for the effective management of skin diseases and for reducing high treatment costs. Regulatory approvals are crucial for bringing new treatments to market and ensuring their safety and efficacy.
Get a glance at the market share of various segments Request Free Sample
The psoriasis segment accounted for USD 11.61 billion in 2018 and showed a gradual increase during the forecast period.
North America is estimated to contribute 36% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
For more insights on the market share of various regions Request Free Sample
The market in North America is experiencing notable growth due to the rising prevalence of various skin conditions in the region. These diseases encompass a broad spectrum of disorders that affect the skin and its appendages, excluding malignant tumors such as melanoma. Chronic diseases like psoriasis, eczema, and dermatitis are among the most common non-cancerous skin conditions, causing discomfort, pain, and cosmetic concerns for affected individuals, thereby impacting their quality of life. Environmental factors, including UV radiation exposure due to ozone layer depletion and genetic predispositions, are significant contributors to the increased incidence of non-cancerous skin diseases. In the intensive care setting, immunocompromised patients are at a higher risk of developing these conditions due to their weakened immune systems.
To address the growing demand for effective therapeutics, various diagnostics and therapeutics are being developed. These include targeted therapies like immunotherapy and chemotherapy, cellular therapy using Amtagvi (lifileucel), and the use of extracellular vesicles. Genetic mutations play a crucial role in the development of non-cancerous skin diseases, making precision medicine an essential approach in their treatment. Branded and generic drugs are available for various non-cancerous skin diseases. Broad local excision and skin grafting are common surgical procedures used in their treatment. Immunotherapies like immune checkpoint inhibitors, such as Pembrolizumab and Nivolumab, are increasingly being used to treat non-cancerous skin diseases.
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The high prevalence of skin diseases is the key driver of the market. The global market for non-cancerous skin diseases therapeutics is significant due to the high prevalence of various skin conditions worldwide. Factors contributing to this include bacterial infections, fungal growth, parasitic infestations, viral outbreaks, genetic predispositions, and immune system compromises. According to the Skin Cancer Foundation, over 125 million individuals are affected by psoriasis globally, and in the US, more than 8 million people live with this chronic disease. Atopic dermatitis, a common type of eczema, impacts approximately 18 million Americans. In intensive care settings, skin diseases can complicate patient care, necessitating diagnostics and therapeutics. While skin cancer, including melanoma and its variants like desmoplastic melanoma, receives considerable attention, non-cancerous skin diseases are equally important.
Ozone layer depletion and UV radiation exposure exacerbate the issue, necessitating early detection and prevention measures. Branded and generic drugs, including immune checkpoint inhibitors like Pembrolizumab and Nivolumab, are essential in treating various skin diseases. Novel immunotherapies and combination therapies are under clinical trials, aiming for regulatory approvals to broaden treatment options. Precision medicine, focusing on individual genetic predispositions, is a promising approach to improving treatment efficacy. Despite these advancements, the high cost of treatment and potential drug resistance remain significant challenges.
Increased focus on microbiome and skin barrier is the upcoming trend in the market. The market has gained significant attention due to the increasing awareness of the intricate relationship between the skin microbiome and skin health. The skin microbiome, comprised of various microorganisms inhabiting the skin's surface, plays a vital role in maintaining skin health by contributing to the skin's natural defense mechanisms, regulating inflammation, and promoting wound healing. Imbalances in the skin microbiome have been linked to the development of several non-cancerous skin diseases, including acne, eczema, dermatitis, and psoriasis. Skin cancer, such as melanoma, is a chronic disease that poses a significant health concern, especially for the immunocompromised and those in intensive care settings.
Melanoma therapeutics have seen advancements in targeted therapies, immunotherapies, and surgery. Immunotherapies, including immune checkpoint inhibitors like Pembrolizumab and Nivolumab, have shown promising results in treating metastatic melanoma and desmoplastic melanoma. Moreover, novel immunotherapies, such as Amtagvi (lifileucel), which utilizes extracellular vesicles, and cellular therapies, are under investigation for their potential in treating various skin diseases. Genetic mutations and predispositions, as well as UV radiation exposure, are significant factors contributing to the development of skin diseases. Early detection and precision medicine are crucial in improving treatment efficacy and addressing drug resistance, which can result in high treatment costs. Clinical trials and regulatory approvals are ongoing to expand the availability of branded and generic drugs, broad local excision, skin grafting, and combination therapies in the market.
Increasing competition from local companies offering generic drugs at low price points is a key challenge affecting the market growth. The market is characterized by intense competition among global and regional players, offering biologics, oral drugs, and topicals. The expiry of patents on branded topical corticosteroids for various skin conditions has led to an influx of generic versions. Despite the advantages of global companies, such as concentrated technical, financial, and marketing resources, wide geographical presence, and strong distribution channels, their branded products are often more expensive than generics. Small- and medium-sized enterprises (SMEs), on the other hand, have limited financial and technical capabilities, leading them to focus on generic manufacturing. Skin diseases, including those non-cancerous, pose a significant challenge due to their chronic nature and the increasing prevalence among immunocompromised individuals.
In intensive care settings, timely diagnostics and therapeutics are crucial. Melanoma, a type of skin cancer, is a major concern due to its metastatic and desmoplastic forms. Targeted therapy, immunotherapy, chemotherapy, and cellular therapy are popular approaches for melanoma therapeutics. Novel immunotherapies, such as Amtagvi (lifileucel), and extracellular vesicles, are gaining attention. Genetic mutations, UV radiation exposure, and genetic predispositions are key factors driving the need for effective therapeutics. Early detection and precision medicine are crucial for treatment efficacy, but high costs and drug resistance remain significant challenges. Clinical trials and regulatory approvals are essential for bringing new treatments to market. Ozone layer depletion and its impact on skin diseases add to the market's complexity.
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Sanofi SA: The company offers non-tumorous skin disease therapeutics such as Dupixent used for treating moderate-to-severe atopic dermatitis for children aged between 6 months to 5 years.
The market research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The market is witnessing significant growth due to the increasing prevalence of chronic skin diseases and the development of advanced therapeutic options. Skin diseases, such as melanoma, desmoplastic melanoma, and other non-melanoma skin cancers, are a major health concern worldwide. According to the Skin Cancer Foundation, over 5 million cases of non-melanoma skin cancers are diagnosed each year in the US alone. The market for Non-Cancerous Skin Diseases Therapeutics includes various treatment modalities such as surgery, immunotherapy, targeted therapy, chemotherapy, cellular therapy, and diagnostics.
Branded drugs and generic drugs are used in the treatment of these conditions. Targeted therapies, immunotherapies, and combination therapies are gaining popularity due to their high treatment efficacy and precision medicine approach. Novel immunotherapies, such as Amtagvi (lifileucel), and extracellular vesicles, are showing promising results in clinical trials.
However, high treatment costs and drug resistance are major challenges in the market. Early detection and regulatory approvals are crucial to improving treatment outcomes and reducing healthcare costs. Ozone layer depletion and genetic mutations are significant factors contributing to the increasing prevalence of skin diseases. Immunotherapy, including immune checkpoint inhibitors like Pembrolizumab and Nivolumab, is a promising area of research in the market. The market is expected to grow at a steady pace due to the increasing demand for effective and affordable treatment options and the ongoing research and development in the field.
Market Scope |
|
Report Coverage |
Details |
Page number |
176 |
Base year |
2023 |
Historic period |
2018-2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 9.88% |
Market Growth 2024-2028 |
USD 25.22 billion |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
8.95 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 36% |
Key countries |
US, Canada, Germany, UK, and China |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
AbbVie Inc., Amgen Inc., AstraZeneca Plc, Bayer AG, Bristol Myers Squibb Co., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Galderma SA, GlaxoSmithKline Plc, Incyte Corp., LEO Pharma AS, Merck KGaA, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., UCB SA, Viatris Inc., and XBiotech Inc. |
Market dynamics |
Parent market analysis, market growth inducers and obstacles, market forecast, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, market condition analysis for the forecast period |
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Therapy Area
7 Market Segmentation by Route of Administration
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.